Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Moi, Line L H ^a,c   Flågeng, Marianne H ^a,b   Gjerde, Jennifer ^a,b   Madsen, Andre ^a,b   Røst, Therese H ^a   Gudbrandsen, Oddrun A ^a   Lien, Ernst A ^a,b   Mellgren, Gunnar ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Breast cancer; HER; HER 2; SRC 1; SRC 2 TIF 2; SRC 3 AIB1; Tamoxifen

Indexed keywords

DIMETHYLBENZ[A]ANTHRACENE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MESSENGER RNA; NUCLEAR RECEPTOR COACTIVATOR 2; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; TRANSCRIPTION FACTOR ETS 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER SIZE; CANCER TISSUE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TISSUE LEVEL; FEMALE; GENE EXPRESSION PROFILING; GENETIC CORRELATION; NONHUMAN; RAT; TREATMENT DURATION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BODY WEIGHT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; NUCLEAR RECEPTOR COACTIVATORS; PROTO-ONCOGENE PROTEIN C-ETS-2; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RNA, MESSENGER; TAMOXIFEN; TUMOR BURDEN;

EID: 84865289242     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-247     Document Type: Article

References (59)

1. Foster JS, Henley DC, Ahamed S, Wimalasena J. Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol Metab 2001, 12:320-327. 10.1016/S1043-2760(01)00436-2, 11504672.
2. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group.
3. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007, 36:5815-5824.
4. Lonard DM, Kumar R, O'Malley BW. Minireview: the SRC family of coactivators: an entrée to understanding a subset of polygenic diseases?. Mol Endocrinol 2010, 24:279-285. 10.1210/me.2009-0276, 2817609, 19846539.
5. Hudelist G, Czerwenka K, Kubista E, Marton E, Pischinger K, Singer CF. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res Treat 2003, 78:193-204. 10.1023/A:1022930710850, 12725419.
6. Haugan Moi LL, Flågeng MH, Gandini S, Guerrieri-Gonzaga A, Bonanni B, Lazzeroni M, Gjerde J, Lien EA, DeCensi A, Mellgren G. Effect of low dose tamoxifen on Steroid Receptor Coactivator 3/Amplified in Breast Cancer 1 in normal and malignant human breast tissue. Clin Cancer Res 2010, 16:2176-2186. 10.1158/1078-0432.CCR-09-1859, 20332317.
7. Lydon JP, O'Malley BW. Minireview: steroid receptor coactivator-3: a multifarious coregulator in mammary gland metastasis. Endocrinology 2011, 152:19-25. 10.1210/en.2010-1012, 3219052, 21047941.
8. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997, 277:965-968. 10.1126/science.277.5328.965, 9252329.
9. Murphy LC, Simon SL, Parkes A, Leygue E, Dotzlaw H, Snell L, Troup S, Adeyinka A, Watson PH. Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res 2000, 60:6266-6271.
10. Bouras T, Southey MC, Venter DJ. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res 2001, 61:903-907.
11. List HJ, Reiter R, Singh B, Wellstein A, Riegel AT. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat 2001, 68:21-28. 10.1023/A:1017910924390, 11678305.
12. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Nat Cancer Inst 2004, 96:926-935. 10.1093/jnci/djh166, 15199112.
13. Wang LH, Yang XY, Zhang X, An P, Kim HJ, Huang J, Clarke R, Osborne CK, Inman JK, Appella E, Farrar WL. Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell 2006, 10:487-499. 10.1016/j.ccr.2006.09.015, 17157789.
14. Kressler D, Hock MB, Kralli A. Coactivators PGC-1b and SRC-1 interact functionally to promote the agonist activity of the selective estrogen receptor modulator tamoxifen. J Biol Chem 2007, 282:26897-26907. 10.1074/jbc.M705596200, 17631495.
15. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003, 95:353-361. 10.1093/jnci/95.5.353, 12618500.
16. Fleming FJ, Myers E, Kelly G, Crotty TB, McDermott EW, O'Higgins NJ, Hill ADK, Young LS. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J Clin Pathol 2004, 57:1069-1074. 10.1136/jcp.2004.016733, 1770462, 15452162.
17. Redmond AM, Bane FT, Stafford AT, McIlroy M, Dillon MF, Crotty TB, Hill AD, Young LS. Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clin Cancer Res 2009, 15:2098-2106. 10.1158/1078-0432.CCR-08-1649, 19276281.
18. Flågeng MH, Haugan Moi LL, Dixon JM, Geisler J, Lien EA, Miller WR, Lønning PE, Mellgren G. Nuclear receptor coactivators and HER-2/neu are upregulated in breast cancer patients during neoadjuvant treatment with aromatase inhibitors. Brit J Cancer 2009, 101:253-260.
19. Huggins C, Grand LC, Brilliantes FP. Mammary cancer induced by a single feeding of polynuclear hydrocarbons, and its suppression. Nature 1961, 189:204-207. 10.1038/189204a0, 13716610.
20. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor dimerization in development and cancer. EMBO J 2000, 19:3159-3167. 10.1093/emboj/19.13.3159, 313958, 10880430.
21. Gjerde J, Kisanga ER, Hauglid M, Holm PI, Mellgren G, Lien EA. Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr A 2005, 1082:6-14. 10.1016/j.chroma.2005.01.004, 16038189.
22. Kisanga ER, Gjerde J, Schjøtt J, Mellgren G, Lien EA. Tamoxifen administration and metabolism in nude mice and nude rats. J Steroid Biochem Mol Biol 2003, 84:361-367. 10.1016/S0960-0760(03)00051-7, 12711024.
23. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 1991, 51:4837-4844.
24. Lauritsen KJ, List HJ, Reiter R, Wellstein A, Riegel AT. A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. Oncogene 2002, 21:7147-7155. 10.1038/sj.onc.1205943, 12370804.
25. Lonard DM, Tsai SY, O'Malley BW. Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins. Mol Cell Biol 2004, 24:14-24. 10.1128/MCB.24.1.14-24.2004, 303341, 14673139.
26. Dati C, Antoniotti S, Tavema D, Perroteau I, De Bortoli M. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 1990, 5:1001-1006.
27. Read LD, Keith D, Slamon DJ, Katzenellenbogen BS. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 1990, 50:3947-3951.
28. Antoniotti S, Tavema D, Maggiora P, Sapei ML, Hynes NE, DeBortoli M. Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms. Br J Cancer 1994, 70:1095-1101. 10.1038/bjc.1994.454, 2033707, 7526884.
29. Newman SP, Bates NP, Vernimmen D, Parker MG, Hurst HC. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 2000, 19:490-497. 10.1038/sj.onc.1203416, 10698518.
30. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008, 456:663-666. 10.1038/nature07483, 2920208, 19005469.
31. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003, 144:1032-1044. 10.1210/en.2002-220620, 12586780.
32. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16:1647-1655. 10.1093/emboj/16.7.1647, 1169769, 9130710.
33. DiGiovanna MP, Lerman MA, Coffey RJ, Muller WJ, Cardiff RD, Stern DF. Active signaling by Neu in transgenic mice. Oncogene 1998, 17:1877-1884. 10.1038/sj.onc.1202091, 9778054.
34. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999, 18:2149-2164. 10.1093/emboj/18.8.2149, 1171299, 10205169.
35. Hudelist G, Singer CF, Manavi M, Pischinger K, Kubista E, Czerwenka K. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat 2003, 80:353-361. 10.1023/A:1024929522376, 14503808.
36. Neve RM, Sutterlüty H, Pullen N, Lane HA, Daly JM, Krek W, Hynes NE. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 2000, 19:1647-1656. 10.1038/sj.onc.1203470, 10763821.
37. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 2007, 120:1874-1882. 10.1002/ijc.22423, 17266042.
38. Myers E, Hill ADK, Kelly G, McDermott EW, O'Higgins NJ, Buggy Y, Young LS. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin Cancer Res 2005, 11:2111-2122. 10.1158/1078-0432.CCR-04-1192, 15788656.
39. Wang S, Yuan Y, Liao L, Kuang SQ, Tien JC, O'Malley BW, Xu J. Disruption of the SRC-1 gene mice suppresses breast cancer metastasis without affecting primary tumor formation. Proc Natl Acad Sci US 2009, 106:151-156.
40. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995, 10:2435-2446.
41. McIlroy M, Fleming FJ, Buggy Y, Hill ADK, Young LS. Tamoxifen induces ER-alpha - SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence. Endocr Relat Cancer 2006, 13:1135-1145. 10.1677/erc.1.01222, 17158759.
42. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992, 24:85-95. 10.1007/BF01961241, 8095168.
43. Miller DL, El-Ashry D, Cheville AL, Liu Y, McLeskey SW, Kern FG. Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Differ 1994, 5:1263-1274.
44. Zhao W, Zhang Q, Kang X, Jin S, Lou C. AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells. Biochem Biophys Res Commun 2009, 380:699-704. 10.1016/j.bbrc.2009.01.155, 19285025.
45. Feng W, Webb P, Nguyen P, Liu X, Li J, Karin M, Kushner PJ. Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway. Mol Endocrinol 2001, 15:32-45. 10.1210/me.15.1.32, 11145737.
46. Rowan BG, Garrison N, Weigel NL, O'Malley BW. 8-bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Mol Cell Biol 2000, 20:8720-8730. 10.1128/MCB.20.23.8720-8730.2000, 86491, 11073973.
47. Font De Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000, 20:5041-5047. 10.1128/MCB.20.14.5041-5047.2000, 85954, 10866661.
48. Wu RC, Qin J, Hashimoto Y, Wong J, Xu J, Tsai SY, Tsai MJ, O'Malley BW. Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator activity by IΚB kinase. Mol Cell Biol 2002, 22:3549-3561. 10.1128/MCB.22.10.3549-3561.2002, 133790, 11971985.
49. Wu RC, Qin J, Yi P, Wong J, Tsai SY, Tsai MJ, O'Malley BW. Selective phosphorylation of the SRC-3/AIB coactivator integrate genomic responses to multiple cellular signaling pathways. Mol Cell 2004, 15:937-949. 10.1016/j.molcel.2004.08.019, 15383283.
50. Pasqualini JR, Sumida C, Giambiagi N. Pharmacodynamics and biological effects of antiestrogens in different models. J Steroid Biochem 1988, 31:613-643. 10.1016/0022-4731(88)90013-1, 3059059.
51. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004, 85:151-159. 10.1023/B:BREA.0000025406.31193.e8, 15111773.
52. Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, Mellgren G, Steen VM, Lien EA. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 2008, 19:56-61.
53. Stearns V, Rae JM. Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?. Expert Rev Mol Med 2008, 10:e34. 3133663, 19019258.
54. Parte P, Kupfer D. Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab Dispos 2005, 33:1446-1452. 10.1124/dmd.104.000802, 15987777.
55. Lien EA, Solheim E, Kvinnsland S, Ueland PM. Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 1988, 48:2304-2308.
56. Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 1989, 49:2175-2183.
57. Kisanga ER, Haugan Moi LL, Gjerde J, Mellgren G, Lien EA. Induction of hepatic drug-metabolising enzymes and tamoxifen metabolite profile in relation to administration route during low-dose treatment in nude rats. J Steroid Biochem Mol Biol 2005, 94:489-498. 10.1016/j.jsbmb.2004.12.037, 15876414.
58. Karimian E, Chagin AS, Gjerde J, Heino T, Lien EA, Ohlsson C, Sävendahl L. Tamoxifen impairs both longitudinal and cortical bone growth in young male rats. J Bone Miner Res 2008, 23:1267-1277. 10.1359/jbmr.080319, 18348701.
59. Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C, Serrano D, Pelosi G, Decensi A, Lien EA. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 2004, 10:2336-2343. 10.1158/1078-0432.CCR-03-0538, 15073109.